Competing Interests
GCI received consultancy or advisory role fees from Novartis, Kura Oncology and NuProbe and received research funding from Celgene, Novartis, Kura Oncology, Syndax Pharmaceuticals, Merck, Cullinan Oncology and NuProbe. IA received fees for consulting or advisory roles from Amgen, Pfizer, Jazz, AbbVie, and Agios, research funding from AbbVie and Macrogenics, and fees from Amgen, Pfizer, Jazz, AbbVie, and Agios. JDP has an advisory role with Incyte and RiverVest Venture Partners, has served as a board member or member of an advisory committee for RiverVest Venture Partners, Magenta, hC Bioscience, Inc. and WUGEN, has received research funding from NeoImmune Tech, Macrogenics, Incyte, Bioline Rx and WUGEN and holds patents or patents pending for UCART7 for the treatment of T-ALL, VLA-4 inhibitors for stem cell mobilization and NT-I7 for CART expansion. RS served on the AbbVie steering committee and advisory boards of AbbVie, AvenCell, CTI Pharma, Kura One, Genentech, Actinium, Arog, BMS, Boston Pharmaceuticals, GSK, Janssen, Jazz, Novartis, Syros, Takeda, Elevate Bio, Syndax Geneesmiddelen, Gemoab, BergGenBio, Foghorn Tera, Aprea, Innate, Actinium, and OncoNova; served as DSMB for Aptevo, Epizyme, Takeda, and Syntrix/ACI Clinical; about the BerGenBio focus group; and on AML Expert Council of GSK and Grand Rounds of Jazz Pharmaceuticals. MA served on the advisory boards of Kite Pharma and Syndax Pharmaceuticals. MJT has an advisory or advisory role at AbbVie and CVS, has an expert role at Apotex, and has received research funding from AbbVie, Gilead Sciences, Janssen, Merck, Pharmacyclics, Syndax Pharmaceuticals, TG Therapeutics, and Tolero. MRP played a leading role at ION Pharma; received honoraria from Pfizer, Pharmacyclics, Bayer, Janssen Oncology, Genentech and Adaptive Biotechnologies; has an advisory or advisory role at Pharmacyclics/Janssen and Pfizer/EMD Serono; served on the Speakers’ Bureau of Exelixis, Genentech/Roche, Taiho Pharmaceutical, and Celgene; and received research funding from Acerta Pharma, ADC Therapeutics, Agenus, Aileron Therapeutics, AstraZeneca, BioNTech AG, Boehringer Ingelheim, Celgene, Checkpoint Therapeutics, CicloMed, Clovis Oncology, Cyteir Therapeutics, Daiichi Sankyo, Lilly, EMD Serono, Evelo Therapeutics, FORMA Therapeutics, Genentech/Roche, Gilead Sciences, GlaxoSmithKline, H3 Biomedicine, Hengrui Therapeutics, Hutchison MediPharma, Ignyta, Incyte, Jacobio, Janssen, Klus Pharma, Kymab, Loxo, LSK Biopartners, Lycera, Macrogenics, Merck, Millennium, Mirati Therapeutics, Moderna Therapeutics , Pfizer, Placon, Portola Pharmaceuticals, Prelude Therapeutics, Ribon Therapeutics, Seven and Eight Biopharmaceuticals, Syndax Pharmaceuticals, Taiho Pharmaceutical, Takeda, Tesaro, TopAlliance BioSciences, Inc., Vigeo, ORIC, Artios, IgM Biosciences, Puretech, BioTheryX, Black Diamond Therapeutics , IgM Biosciences, NGM Biopharmaceuticals, Nurix, PureTech, Relay Therapeutics, Samumed, Silicon Therapeutics, TeneoBio, Tre adwel l Therapeutics, Zymeworks, Olema, Adagene, Astellas, NGM, Accutar Biotech, TeneoBio, Novartis, Compugen, Black Diamond Therapeutics, MabSpace Biosciences, Immunogen, and Blueprint Pharmaceuticals. DSD has an advisory or advisory role to Tempus, Inc. S. Shenoy has an advisory or advisory role with Artio, BMS and Takaeda. HK received honoraria/advisory board/consulting fees from AbbVie, Amgen, Amphista, Ascentage, Astellas, Biologix, Curis, Ipsen Biopharmaceuticals, KAHR Medical, Labcorp, Novartis, Pfizer, Shenzhen Target Rx, Stemline, and Takeda; and received research funding from AbbVie, Amgen, Ascentage, BMS, Daiichi Sankyo, Immunogen, Jazz and Novartis. SAA has acquired stock or other ownership in Neomorph, Inc., C4 Therapeutics, Cyteir Therapeutics, Accent Therapeutics, and Mana Therapeutics; has an advisory or advisory role with Neomorph, Inc., C4 Therapeutics, Cyteir Therapeutics, Accent Therapeutics, Mana Therapeutics, and Twentyeight-Seven Therapeutics; received research funding from Syndax Pharmaceuticals and Janssen; and holds patents, royalties and other intellectual property for MENIN inhibition in NPM1 AML: WO/2017/132398A1. GR is a former employee of Syndax Pharmaceuticals and a current employee of Boston Pharmaceuticals. RGB is an employee of Syndax Pharmaceuticals and has stock or other property in Syndax Pharmaceuticals. MLM, PO and GMM are employees of Syndax Pharmaceuticals. MLM has an advisory or advisory role in Nuvalent, owns patents, royalties and other intellectual property in Syndax Pharmaceuticals and Nuvalent, and has stock or other property in Syndax Pharmaceuticals and Johnson & Johnson. PO has consultative or advisory roles with Patrys and Twentyeight-Seven Therapeutics, owns patents, royalties and other intellectual property in Syndax Pharmaceuticals, and has stock or other property in Syndax Pharmaceuticals. GMM has an advisory or advisory role in Syndax Pharmaceuticals, owns patents, royalties and other intellectual property in Syndax Pharmaceuticals, and has stock or other property in Syndax Pharmaceuticals. YG is an employee of Syndax Pharmaceuticals and has stock or other property in Syndax Pharmaceuticals and AstraZeneca. S. Smith has an advisory or advisory role at Syndax Pharmaceuticals. EMS has advisory or advisory roles with Gilead, CTI Biopharma, Epizyme, AbbVie, Pinotbio, Neoleukin Genesis, Genentech, Jazz, Novartis, Celgene, Calithera, Takeda, Janssen, BMS, Kronos, Kura, Auron, Syndax Pharmaceuticals, Servier, Agios and Remix and received research funding from Biotheryx, Agios, Servier, Eisai, BMS, Bayer, Syndax, Syros and Loxo. BC, FP, JAP, NS and VK declare no conflict of interest.